Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019402 | 0.78 | MTNR1A (0.34) | ALDH1A1EGFRMAPTKMT2A | |
| SCHEMBL3342299 | 0.76 | MEN1 (0.39) | EGFRSMN1; SMN2MEN1KMT2AERBB2 | |
| SCHEMBL3030672 | 0.72 | KDM1A (0.59) | KDM1AACP1ALDH1A1MAPK1EGFR | |
| SCHEMBL3031840 | 0.72 | NOX1 (0.31) | — | |
| SCHEMBL4465723 | 0.68 | ALDH1A1 (0.43) | ALDH1A1MAPK1ALOX15 | |
| SCHEMBL4652904 | 0.68 | BACE1 (0.36) | ALDH1A1MAPK1GAA | |
| SCHEMBL13302934 | 0.68 | DUT (0.34) | APP | |
| SCHEMBL7717528 | 0.68 | DUT (0.37) | ALDH1A1 | |
| SCHEMBL28557487 | 0.68 | KDM1A (0.63) | KDM1AMAP3K5ACP1ALDH1A1MAPK1 | |
| SCHEMBL10145174 | 0.68 | CYP4F2 (0.41) | ALDH1A1MAPK1MAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067900-B2 | Diaminophenothiazine compounds, a method for preparing same and uses thereof | PHARMA HYDRO DEVELOPMENT—P.H.D. (FR) | 2015-06-30 | — | — | US | disclosed |
| EP-2185531-B1 | Diaminophenothiazine compounds, a method for preparing same and uses thereof | PHARMA HYDRO DEV P H D (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2185531-A2 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | Pharma Hydro Development - P.H.D. (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044054-A2 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | AOC1, DDT, DDC | KDM1A 3081/4885MAP3K5 955/4885ACP1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.